Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

639
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
639
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

5.1K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

1.8K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.4K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk-based approach to setting sterile filtration microbial bioburden limits - Focus on biotech-derived products.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2023
See all related articles

Related Experiment Video

Updated: Feb 10, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.2K

lnterleukin-1 Receptor Antagonist.

Andrew C Lennard

    Critical Reviews in Immunology
    |May 19, 2018
    PubMed
    Summary

    Interleukin-1 receptor antagonist (IL-1ra) has two forms: secreted (sIL-1ra) and intracellular (icIL-1ra). Research explores their genetics, regulation, and roles in inflammatory diseases.

    Area of Science:

    • Immunology
    • Molecular Biology
    • Genetics

    Background:

    • Interleukin-1 receptor antagonist (IL-1ra) is a unique cytokine receptor antagonist.
    • IL-1ra has two known forms: secreted (sIL-1ra) and intracellular (icIL-1ra).
    • IL-1ra is implicated in the pathogenesis of acute and chronic inflammatory diseases.

    Purpose of the Study:

    • To review the genetics of the IL-1RN gene.
    • To explore mechanisms of IL-1ra gene activation for sIL-1ra and icIL-1ra production.
    • To discuss the biological roles of IL-1ra in health and disease.

    Main Methods:

    • Review of existing literature on IL-1ra genetics and regulation.
    • Analysis of gene activation mechanisms.
    • Discussion of biological roles based on animal models and in vitro studies.

    More Related Videos

    A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
    07:41

    A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

    Published on: February 20, 2018

    9.5K
    Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
    07:20

    Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

    Published on: May 19, 2020

    7.7K

    Related Experiment Videos

    Last Updated: Feb 10, 2026

    Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
    10:51

    Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

    Published on: November 15, 2013

    13.2K
    A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
    07:41

    A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

    Published on: February 20, 2018

    9.5K
    Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
    07:20

    Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

    Published on: May 19, 2020

    7.7K

    Main Results:

    • The IL-1RN gene encodes both sIL-1ra and icIL-1ra through alternative first exon usage.
    • Two distinct promoters regulate the expression of sIL-1ra and icIL-1ra.
    • Animal models show therapeutic potential for exogenous IL-1ra in inflammatory conditions.

    Conclusions:

    • IL-1ra, in its two forms, plays a significant role in inflammatory disease pathogenesis.
    • Understanding IL-1ra gene regulation is crucial for exploring its therapeutic potential.
    • Further investigation is needed for recombinant IL-1ra in human disease management.